Icad Inc Stock Price, News & Analysis

iCAD has announced a strategic partnership with Google Health, marking the latter's first collaboration with a mammography AI vendor. This agreement aims to integrate Google’s AI technology into iCAD’s portfolio, enhancing their breast cancer detection capabilities. The collaboration is expected to improve the accuracy and efficiency of mammography and expand access to innovative breast imaging solutions globally. iCAD will leverage Google Cloud’s infrastructure to transition its offerings to cloud-based solutions, enhancing scalability and reaching underserved regions.

NASHUA, N.H., Nov. 15, 2022 - iCAD, a leader in medical technology, has announced that CEO Stacey Stevens will participate in the 13th Annual Craig-Hallum Alpha Select Conference on November 17 in New York City. The event will provide a platform for investor engagement through one-on-one meetings. This participation highlights iCAD's commitment to advancing cancer detection and therapy solutions. Interested investors can arrange meetings via Craig-Hallum representatives. For more details, visit www.icadmed.com.

iCAD (NASDAQ: ICAD) will be prominently featured at HLTH 2022, a major health industry conference held from November 13-16 at the Venetian Hotel in Las Vegas. The event will see over 8,500 senior leaders collaborate on pressing healthcare issues. iCAD's President and CEO, Stacey Stevens, will speak about enhancing breast cancer screening through AI on November 14, from 1:55 to 2:35 pm in the Google Health Theater Room. This participation underscores iCAD's commitment to innovative cancer detection and therapy solutions.

iCAD reported a Q3 2022 revenue of $6.4 million, down 32% year-over-year, attributed to a 49% drop in product revenue. Cost-cutting measures aim to reduce expenses by over $3 million annually. A strategic shift towards a subscription-based model has resulted in increased demand, with more subscriptions booked in Q3 than in the first half of 2022. The new Subscription Annual Recurring Revenue (S-ARR) metric aims to highlight progress in this area. The net loss for Q3 2022 was $3.9 million, compared to $2.2 million in Q3 2021.

iCAD has announced a strategic multi-year partnership with Radiology Partners, the largest radiology practice in the U.S., to expand the adoption of iCAD's Breast AI Suite. This collaboration aims to enhance breast cancer screening access for millions of women nationwide. The agreement includes an initial order from Radiology Partners, enabling the deployment of iCAD's technologies across its expansive network, which serves over 3,000 facilities. The Breast AI Suite incorporates advanced AI tools for improved mammography accuracy and personalized risk evaluation.

iCAD, Inc. (NASDAQ: ICAD) announced it will release its third-quarter financial results for the period ending September 30, 2022, after market close on November 10, 2022. A conference call is scheduled for 4:30 PM ET on the same day, allowing investors and analysts to discuss the outcomes. The information aims to provide insights into the company's ongoing efforts in cancer detection and therapy solutions, reflecting its position as a leader in medical technology.

iCAD, Inc. (NASDAQ: ICAD) has entered a strategic collaboration with Solis Mammography to enhance cardiovascular disease (CVD) detection in women through mammography. The partnership aims to develop an AI solution leveraging ProFound AI technology to identify breast arterial calcifications, a key indicator of heart disease risk. The initiative addresses a critical health issue, as heart disease is the leading cause of death among women in the U.S. This collaboration builds upon their existing relationship, with Solis Mammography already using iCAD's technology across its network.

iCAD, a leader in medical technology focused on cancer detection and therapy, announced its participation in the Lake Street Capital Markets 6th Annual Best Ideas Growth Conference on September 14, 2022, in New York City. Stacey Stevens, President and CEO, will meet with investors at the event. Interested parties can schedule meetings through Lake Street Capital representatives. iCAD continues to innovate with its ProFound AI technology, though it faces potential risks and uncertainties, including market acceptance and regulatory factors.

iCAD announces the growing adoption of its Breast AI Suite through a flexible subscription model, making it easier for hospitals and imaging centers to deploy advanced breast cancer detection technologies. The subscription model reduces upfront costs and allows for easier updates and scalability. Key offerings include ProFound AI, the first FDA-cleared AI for 3D mammography, and PowerLook Density Assessment. This innovative approach aligns with trends in the healthcare industry, which sees subscription models growing significantly. iCAD aims to enhance patient care while establishing recurring revenue streams.